18 July 2019 / PARIS - Dechert advised Abivax, a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, as part of its €12M capital increase entirely subscribed at market price by Sofinnova Crossover I, a fund managed by Sofinnova Partners.
This capital increase enables Abivax, now valued at more than €100 million, to secure funding for its clinical trials until mid-2020.
Dechert's team of lawyers was led by Alain Decombe and Charles Cardon, with assistance from Quentin Durand and Vianney Toulouse.
About Dechert
Dechert is a leading global law firm with 26 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.
Related Professionals
